TMCnet News

Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET
[May 31, 2023]

Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET

SOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to ask questions of Company management. The first event will be a fireside chat with Vaxart executives on Thursday, June 15 at 11 a.m. ET.

“Investor support is the lifeblood of a developing biotechnology company, and we are excited to further the ongoing dialogue with our shareholders,” said Andrei Floroiu, Vaxart’s Chief Executive Officer. “Our leadership team communicates with investors through several channels, and this program provides us with an additional means to keep investors informed about the Company. We look forward to sharing our progress as we advance our oral vaccine platform.”

The new investor communication program is available in the Investor Resources section of Vaxart’s Investor Relations webpage. Individuals will have the opportunity to submit questions in advance of each event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently inclue pill vaccines designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.


Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "should," "believe," "could," "potential," "will," "expected," "anticipate," "plan," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial data; and Vaxart's expectations with respect to the effectiveness of its product candidates. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes.

Please also refer to the risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.


Vaxart Media Relations:  Investor Relations:?????? 
Mark?Herr???? Andrew Blazier
Vaxart, Inc.  Finn Partners
[email protected]??? [email protected]?? 
(203) 517-8957????? (646) 871-8486   

Primary Logo

[ Back To's Homepage ]